Drug Trial Radar · NCT06421636
A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body
Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
19
Actual
Start
Sep 30, 2024
Primary completion
Dec 3, 2026
Study completion Dec 3, 2026
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- May 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental drug called REGN7999 (called "study drug"). The study is focused on patients with non-transfusion dependent beta-thalassemia. The aim of the study is to see how safe and effective the study drug is. The study is looking at several other research questions, including: * Whether the study drug lowers extra iron levels in the body * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Conditions
- Non-Transfusion Dependent Beta-Thalassemia (NTDT)
Interventions
REGN7999Drug
Administered subcutaneous (SC)
PlaceboDrug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Liver Iron Concentration (LIC) by R2* Magnetic Resonance Imaging (MRI)Time frame: At week 24
- Incidence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to week 72
- Severity of TEAEsTime frame: Up to week 72
Locations
26 sites in 9 countries. Site status is shown where the registry gives one.
Weill Cornell Medicine
New York, New York
K Eristavi National Center of Experimental and Clinical Surgery
Tbilisi, Georgia
Medinvest Institute of Hematology and Transfusiology Limited
Tbilisi, Georgia
University Hospital of Ioannina
Ioannina, Greece
Children's Hospital Agia Sophia
Athens, Attica, Greece
Laiko General Hospital of Athens
Athens, Attica, Greece
Hemato-Oncology Clinic Ahmedabad PVT. LTD.
Ahmedabad, Gujarat, India
Nirmal Hospital Pvt. Ltd - Surat
Surat, Gujarat, India
Amrita Institute of Medical Sciences and Research Centre (AIMS)
Kochi, Kerala, India
K J Somaiya Super Specialty Hospital & Research Centre
Mumbai, Maharashtra, India
All India Institute of Medical Sciences, New Delhi
New Delhi, National Capital Territory of Delhi, India
Indraprastha Apollo Hospitals
New Delhi, National Capital Territory of Delhi, India
JK Lon Hospital
Jaipur, Rajasthan, India
Day Hospital Thalassemia and Haemoglobinopathies (DHTE); A.O.U S.Anna
Ferrara, Italy
Hospital Tunku Ampuan Besar Tuanku Aishah Rohani (HPKK UKM)
Kuala Lumpur, Malaysia
Hospital Queen Elizabeth
Kota Kinabalu, Sabah, Malaysia
Sarawak General Hospital
Kuching, Sarawak, Malaysia
Hospital Ampang
Ampang, Selangor, Malaysia
Chulalongkorn University
Bangkok, Thailand
Phramongkutklao Hospital
Bangkok, Thailand
Chiang Mai University
Chiang Mai, Thailand
Srinagarind Hospital
Khon Kaen, Thailand
Songklanagarind Hospital, Prince of Songkla University
Hat Yai, Changwat Songkhla, Thailand
Hacettepe University
Ankara, Turkey (Türkiye)
University College London Hospitals NHS Trust
London, United Kingdom
Imperial College Healthcare NHS Trust
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.